Talk:Pertuzumab: Difference between revisions
Appearance
Content deleted Content added
Assessment: Pharmacology: importance=Low; WikiProject Medicine: importance=Low (assisted) |
→APHINITY confirmatory trial: new section |
||
Line 4: | Line 4: | ||
{{WikiProject Pharmacology |class=start |importance=Low}} |
{{WikiProject Pharmacology |class=start |importance=Low}} |
||
{{WikiProject Medicine |class=start |importance=Low}}}} |
{{WikiProject Medicine |class=start |importance=Low}}}} |
||
== APHINITY confirmatory trial == |
|||
APHINITY is the confirmatory trial for the September 2013 [[accelerated approval]]. [http://www.targetedonc.com/news/phase-iii-trial-results-confirm-adjuvant-pertuzumab-success-in-her2-breast-cancer ''Phase III Trial Results Confirm Adjuvant Pertuzumab Success in HER2+ Breast Cancer''] - [[User:Rod57|Rod57]] ([[User talk:Rod57|talk]]) 18:03, 20 March 2017 (UTC) |
Revision as of 18:03, 20 March 2017
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pertuzumab.
|
This is the talk page for discussing improvements to the Pertuzumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
|
APHINITY confirmatory trial
APHINITY is the confirmatory trial for the September 2013 accelerated approval. Phase III Trial Results Confirm Adjuvant Pertuzumab Success in HER2+ Breast Cancer - Rod57 (talk) 18:03, 20 March 2017 (UTC)